Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 45: 2273-2274, 1999;
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garcia-Barceló, M.
Right arrow Articles by Waye, M. M. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garcia-Barceló, M.
Right arrow Articles by Waye, M. M. Y.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 1999;45:2273-2274.)
© 1999 American Association for Clinical Chemistry, Inc.


Technical Briefs

Frequencies of Defective CYP2C19 Alleles in a Hong Kong Chinese Population: Detection of the Rare Allele CYP2C19*4

Mercè Garcia-Barceló1,a, Lok-Yee Chow1, Helen Fung Kum Chiu1, Yun Kowk Wing1, Dominic Tak Shing Lee1, Kwok Lim Lam1 and Mary Miu Yee Waye2

1 Psychiatry and
2 Biochemistry, The Chinese University of Hong Kong, Hong Kong;
a author for correspondence: fax 852-2646-2284, e-mail b025744{at}mailserv.cuhk.edu.hk

A genetic polymorphism in the metabolism of the anticonvulsant drug mephenytoin in humans is a prime example of interracial and individual variability in drug metabolism. This polymorphism affects the metabolism of several other clinically used drugs, some of which are of interest in psychopharmacotherapy (1). The polymorphic enzyme that 4'-hydroxylates S-mephenytoin is known as CYP2C19 (2). In subjects deficient for CYP2C19, drugs metabolized by this enzyme may be associated with toxic concentrations or therapeutic failure when administered in dosages within the normal dosage range. Depending on the activity of CYP2C19, individuals can be characterized phenotypically as extensive metabolizers or poor metabolizers (PMs) of S-mephenytoin. CYP2C19 is encoded by the CYP2C19 gene, and its defective alleles account for the PM phenotype, which is inherited as an autosomal recessive trait (3). There is a marked interethnic difference in the distribution of this polymorphism, with the PM phenotype found in 2–5% of Caucasians but in 13–23% of Orientals (4)(5). The main defective allele, CYP2C192, accounts for ~75–85% of alleles responsible for the PM phenotype in both Orientals and Caucasians (4). CYP2C193 is extremely rare in the Caucasian population but accounts for almost all of the remaining defec- tive alleles in Orientals (3)(4)(5)(6)(7)(8)(9). Subsequent studies have revealed additional defective CYP2C19 alleles in Caucasian PMs, identifying >=93% of the defective alleles: CYP2C192B (10), CYP2C194 (9), CYP2C195B (11), and CYP2C196 (10). Only one new allele, CYP2C195A (7), has been found in the Chinese Bai population at a very low frequency (0.0025). In addition to the interracial differences in the genetic polymorphism of the CYP2C19 enzyme, Xiao et al. (7) showed a different incidence of the CYP2C192 and CYP2C191 alleles in two Chinese ethnic groups. These differences in allele frequencies were consistent with phenotypic data suggesting that different Chinese ethnic groups may exhibit somewhat different sensitivities to drugs metabolized by CYP2C19. Therefore, it was of interest to us to investigate the CYP2C19 genotype in a Hong Kong Chinese population.

One hundred nineteen unrelated Hong Kong Chinese individuals participated in the genotyping tests. Forty-five patients diagnosed with depressive disorders according to Diagnostic and Statistical Manual IV but without impairment in liver or kidney function, and 74 healthy subjects were included in this study after giving their informed consent. This research project has been approved by the ethics committee of the Chinese University of Hong Kong.

Blood samples (12 mL) were collected in Vacutte® (Greiner) tubes containing EDTA as anticoagulant. DNA was extracted using the Qiamp Blood kit (Qiagen). PCR followed by restriction enzyme analysis of the amplified products was used to identify CYP2C19 alleles as described previously (7)(8)(9)(11).

Binomial probabilities were used to compute the exact confidence intervals for the frequencies. Allele frequencies in different populations were compared with the {chi}2 test.

The allele frequencies are listed in Table 1 . In general, our data were in agreement with the incidence of CYP2C19 alleles reported previously for other Chinese Han populations (Table 1 ). The frequency of the wild-type allele (CYP2C191) appears marginally higher than that found by Xiao et al. (7) for the Chinese Han population studied ({chi}2 = 3.872; P = 0.051).


View this table:
[in this window]
[in a new window]
 
Table 1. Frequencies of CYP2C191 alleles and PM in Chinese.

CYP2C192, CYP2C193, and CYP2C195 have been shown to account for >99% of the defective CYP2C19 alleles in the three main Oriental races, indicating a complete concordance between phenotype and genotype (5)(8). This suggests that other defective alleles are unlikely to contribute to the PM phenotype in these populations. Surprisingly however, one subject (C33) harbored a CYP2C194 allele (Fig. 1 ). To our knowledge, this is the first CYP2C194 allele found in a Chinese individual. CYP2C194 accounted for the predicted phenotype of one PM individual, with a CYP2C192/CYP2C194 genotype, and represented 2.38% of the defective alleles in the PMs.



View larger version (31K):
[in this window]
[in a new window]
 
Figure 1. PCR-restriction fragment length polymorphism mismatch test for CYP2C19*4.

A 195-bp fragment of exon 1 was amplified by PCR, followed by PstI digestion and electrophoresis. The 195-bp product was not digested in individuals (C31, C32, and C34; lanes 1, 2, and 4 from the left) presenting alleles other than CYP2C19*4. The restriction enzyme PstI completely digested the 195-bp PCR-amplified product from CYP2C19*4 allele to yield 167- and 28-bp restriction fragments. The presence of 195- and 167-bp fragments after PstI digestion, as shown in C33 (lane 3 from the left), indicated that this sample was heterozygous for CYP2C19*4.

Twenty-one subjects (17.65%) were genotypically identified as PMs. The incidence of PM genotypes is comparable to the incidences reported for other Chinese groups (Table 1Up ) (5)(7)(12)(13). CYP2C192 and CYP2C193 accounted for 80.95% and 16.66%, respectively, of the defective alleles in the 21 PMs. We did not detect any occurrence of the alleles CYP2C195 (5A, 5B) (7)(11).

The incidence of PMs found in this study differs only from that found in Chinese Dong subjects, which was estimated as 11.1% (17.65%; {chi}2 = 3.02; P = 0.01). The different incidences of PM for different Chinese ethnic groups may reflect differences in sample size and/or in methods. However, further studies on larger samples should be carried out.

In summary, our data were generally in agreement with the prevalence of PMs in the Chinese populations previously genotyped and phenotyped except for the detection of the CYP2C194 allele.


Acknowledgments

We thank R. J. Morgan for reading this article and for helpful comments and criticisms.


References

  1. Lin KM, Anderson D, Poland RE. Ethnicity and psychopharmacology: bridging the gap. Psychiatr Clin N Am 1995;18:635-647. [ISI][Medline] [Order article via Infotrieve]
  2. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, et al. Evidence for a role for 2C19 in metabolism of S-mephenytoin in humans. Biochemistry 1994;33:1743-1752. [Medline] [Order article via Infotrieve]
  3. Brøsen K, de Morais SMF, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 1995;5:312-317. [ISI][Medline] [Order article via Infotrieve]
  4. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin in humans. J Biol Chem 1994;269:15419-15422. [Abstract/Free Full Text]
  5. de Morais SMF, Goldstein JA, Xie H-G, Huang S-L, Lu Y-Q, Xia H, et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995;58:404-412. [ISI][Medline] [Order article via Infotrieve]
  6. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-598. [Abstract]
  7. Xiao Z-A, Goldstein JA, Xie H-G, Blaisdell J, Wang W, Jiang C-H, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 1997;281:604-609. [Abstract/Free Full Text]
  8. Goldstein JA, Ishizaki T, Chiba K, de Morais SMF, Bell D, Krahn PM, Price Evans DA. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian, and American Black populations. Pharmacogenetics 1997;7:59-64. [ISI][Medline] [Order article via Infotrieve]
  9. Ferguson JF, de Morais SMF, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998;284:356-361. [Abstract/Free Full Text]
  10. Ibeanu GC, Goldstein JA, Meyer U, Benhamou S, Bouchardy C, Dayer P, et al. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 1998;286:1490-1495. [Abstract/Free Full Text]
  11. Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C, et al. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 1998;8:129-135. [ISI][Medline] [Order article via Infotrieve]
  12. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-397. [ISI][Medline] [Order article via Infotrieve]
  13. Nowak MP, Sellers EM, Tyndale RF. Canadian native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies. Clin Pharmacol Ther 1998;64:378-383. [ISI][Medline] [Order article via Infotrieve]
  14. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996;6:193-201. [ISI][Medline] [Order article via Infotrieve]



The following articles in journals at HighWire Press have cited this article:


Home page
J Clin PharmacolHome page
O. Q. P. Yin, B. Tomlinson, A. H. L. Chow, M. M. Y. Waye, and M. S. S. Chow
Omeprazole as a CYP2C19 Marker in Chinese Subjects: Assessment of Its Gene-Dose Effect and Intrasubject Variability
J. Clin. Pharmacol., June 1, 2004; 44(6): 582 - 589.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
J. Borlak and T. Thum
Identification of Major CYP2C9 and CYP2C19 Polymorphisms by Fluorescence Resonance Energy Transfer Analysis
Clin. Chem., September 1, 2002; 48(9): 1592 - 1594.
[Full Text] [PDF]


This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garcia-Barceló, M.
Right arrow Articles by Waye, M. M. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garcia-Barceló, M.
Right arrow Articles by Waye, M. M. Y.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Proteomics and Protein Markers


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS